Allergic Asthma Anti-IgE Therapy
Anti-IgE therapy with omalizumab works by binding to (and thereby blocking) the IgE receptors located on the surface of all mast cells and basophils. Omalizumab interrupts IgE's signal to trigger the inflammatory response responsible for the symptoms of allergic asthma.
Anti-IgE therapy has been shown to reduce asthma attacks and lessen symptoms in some people with allergic asthma.
Facts about omalizumab (Xolair):
- Used only in those with elevated IgE in the bloodstream and a positive skin test to an allergen.
- Used in those with allergic asthma who cannot be controlled with corticosteroids.
- Administered as a weekly subcutaneous injection at the doctor's office.
Your doctor can determine if you are a candidate for treatment with omalizumab.
Continue to Allergic Asthma Anti-Leukotrienes
- Chipps BE. Determinants of asthma and its clinical course. Ann Allergy Asthma Immunol. 2004 Oct;93(4):309-15. 
- de Marco R, Locatelli F, Cazzoletti L, Bugiani M, Carosso A, Marinoni A.. Incidence of asthma and mortality in a cohort of young adults: a 7-year prospective study. Respir Res. 2005 Aug 16;6(1):95. 
- Keeley D, McKean M. Asthma and other wheezing disorders of childhood. Clin Evid. 2003 Jun;(9):287-317. 
- Neidell MJ. Air pollution, health, and socio-economic status: the effect of outdoor air quality on childhood asthma. J Health Econ. 2004 Nov;23(6):1209-36. 
- Rees J. ABC of asthma. Prevalence. BMJ. 2005 Aug 20;331(7514):443-5. 
- Vallance G, Thomson NC. Asthma: ten myths debunked. Practitioner. 2004 Nov;248(1664):844-7.